Skyhawk Therapeutics Receives Australian Regulatory Approval to Extend SKY-0515 Treatment Duration in Phase 1 Huntington’s Disease Patient Trial

Posted on by

Australian Human Research Ethics Committees approves SKY-0515 treatment for up to 12 weeks in the company’s ongoing Phase 1 trial in patients with Huntington’s Disease Volumetric MRI measurement is also approved as exploratory study endpoint BOSTON, Dec. 9, 2024 /PRNewswire/ — Skyhawk…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.